STOCKHOLM, Dec. 8, 2019 /PRNewswire/ — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In the data presented, melflufen and dexamethasone demonstrated positive…
Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019
Read Full Article At The Original Source